3. Systemic treatment with epoetin beta reduces the incidence of acute neurological deterioration following SAH If primary endpoints are improved with epoetin beta therapy, the data will be used to formulate the power calculation for design of a Phase III clinical outcome study. However, we will assess clinical outcome at the end of the trial and at discharge to detect any indication of adverse effect after EPO therapy.